Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454701 · ClinicalTrials.gov registry record
Assessment and Tracking of Long-term Alefacept Safety
A clinical trial, sponsored by Astellas Pharma.
- Terminated
- Registry status
- 1,897
- Enrollment target
NCT00454701: Clinical Trial study, sponsored by Astellas Pharma.
NCT00454701 is a clinical trial that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 1,897 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00454701 was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- 1,897 participants
- Enrollment target
Study Summary
Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.
Interventions
- DRUG Alefacept exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,897 participants |
| Start Date | 2003-06 |
| Est. Completion | 2012-02 |
Why NCT00454701 stopped before completion
NCT00454701 is an observational study that tracks outcomes without assigning an intervention. Its 1,897 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Alefacept exposure is the first listed.
NCT00454701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00454701 about?
NCT00454701 is a clinical study titled "Assessment and Tracking of Long-term Alefacept Safety". Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.
What is the current status of trial NCT00454701?
This trial is currently terminated. The enrollment target is 1,897 participants. The study started on 2003-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00454701?
The interventions under investigation include: Alefacept exposure (DRUG).
Who is sponsoring clinical trial NCT00454701?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07308717 · 1,896 participants · Phase 4
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia